Emergent Biosolutions Inc. last reported quarterly results on Nov 2, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $110.0 million (-52.4% year over year) and diluted EPS of -$0.64. It usually reports 30–57 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 25, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Feb 26, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 30–57 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 2, 2026
33 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
110
-52.4%
|
-33
-163.9%
|
-0.64
-170.3%
|
|
Aug 5, 2026
36 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
234
+66.3%
|
-180
-1401.7%
|
-3.49
-1486.4%
|
|
Apr 30, 2026
30 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
156
-29.7%
|
7
-90.0%
|
0.07
-94.1%
|
|
Feb 26, 2026
57 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
149
-23.6%
|
-55
-74.4%
|
-0.96
-66.7%
|
|
Oct 29, 2025
29 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
231
-21.3%
|
51
-55.4%
|
0.91
-55.8%
|
|
Aug 6, 2025
37 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
141
-44.7%
|
-12
+95.8%
|
-0.22
+95.9%
|
|
May 7, 2025
37 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
222
-26.0%
|
68
+655.6%
|
1.19
+600.0%
|
|
Mar 3, 2025
62 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
195
-29.6%
|
-31
+36.8%
|
-0.58
+39.2%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- EBS (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Gaithersburg, MD
- SEC filer status
- Accelerated filer
- SEC CIK
- 1367644
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.